bullish
Sinopharm Group (1099 HK): Industry Tailwind and China Reopening To Drive Growth
767 Views29 Dec 2022 18:42
SUMMARY
- Sinopharm Group Co Ltd H (1099 HK) remains a beneficiary of both VBP and China reopening. Consensus expects double-digit revenue and earnings growth for the company in 2023 and 2024.
- SinoPharm’s acquisition of VBP varieties constantly stood in the leading position in the industry. Through June 2022, China carried out seven batches of VBP, with 294 categories being included.
- With China gradually re-opening, SinoPharm should record accelerated growth in its pharma distribution business. With subsiding COVID-19 cases in Q3, SinoPharm reported 10% YoY and 8% QoQ revenue growth.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Pre-IPO Lu DaoPei Medical Group - Profitability Is Disappointing Despite Big Potential Theoretically03 May 2023
- Pre-IPO YSB Inc (YSB.HK) - The Business Model Is Facing Challenges26 Apr 2023
- Sinopharm Group (1099 HK): Strong 2022 Results; Double-Digit Top and Bottom-Line Growth to Continue06 Apr 2023
- Sinopharm Group (1099 HK): Industry Tailwind and China Reopening To Drive Growth29 Dec 2022
- Sinopharm Group (1099 HK): Stable Pharma Distribution Business Despite Weak Demand for Vaccine12 Jan 2022
x